{
  "source": "PA-Med-Nec-Methyldopa.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2308-3\nProgram Prior Authorization/Medical Necessity\nMedication Methyldopa\nP&T Approval Date 6/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nMethyldopa is an aromatic-amino-acid decarboxylase inhibitor indicated for hypertension.\nThe American Heart Association recommends methyldopa as a widely established first-line\noption in the treatment of hypertension in pregnancy. Outside of pregnancy, methyldopa has\nlimited utilization due to significant adverse events.\n2. Coverage Criteriaa:\nA. Methyldopa will be approved based on both of the following criteria:\n1. Patient is pregnant\n-AND-\n2. For the treatment of hypertension\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n4. References:\n1. Methyldopa [package insert]. Conger, NY: Chartwell RX, LLC; November 2022.\n2. Garovic VD, Dechend R, Karumanchi SA, et al. Hypertension in Pregnancy: Diagnosis, Blood\nPressure Goals, and Pharmacotherapy: A Scientific Statement from the American Heart\nAssociation. Hypertension. 2022; 79: 321-e41.\n3. Guideline for the pharmacological treatment of hypertension in adults. Geneva: World Health\nOrganization; 2021. Licence: CC BY-NC-SA 3.0 IGO.\n© 2025 UnitedHealthcare Services, Inc.\n1\n4. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the\nPrevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report\nof the American College of Cardiology/American He",
    "APA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the\nPrevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report\nof the American College of Cardiology/American Heart Association Task Force on Clinical\nPractice Guidelines.\nProgram Prior Authorization/Medical Necessity – Methyldopa\nChange Control\n6/2023 New program\n5/2024 Annual review with no changes.\n5/2025 Annual review with no changes.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}